AI-generated · cited to primary sources · not investment advice · How we research
Intuitive Surgical, Inc. - Common Stock
Our verdict on Intuitive Surgical, Inc. - Common Stock isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
Management successfully closed the acquisition of the da Vinci and Ion distribution businesses (abmedica, Abex, Excelencia Robótica) on March 1, 2026, within the guided H1 2026 timeline. (2 met across 2 tracked commitments)
“The Company expects to complete the transaction in the first half of 2026, subject to applicable regulatory approvals and customary closing conditions.”
While the 2025 full-year total is not explicitly restated, the 10-Q confirms that capital expenditures did increase in 2025 as planned to build infrastructure. (1 met across 1 tracked commitment)
“We intend to continue to fund our capital investments with cash generated from operations.”
The company has moved past the Q4 2025 adoption window and is now reporting under updated tax disclosure standards, including discussions on Pillar Two and the OBBBA. (2 met across 2 tracked commitments)
“The Company plans to adopt ASU 2023-09 during the fourth quarter of 2025 for its annual report using a prospective transition method”
The commitment to higher costs was realized; Q1 2026 results show that higher tariff expenses partially offset product gross margin gains and contributed to a decrease in service gross margin. (1 met across 1 tracked commitment)
“Based on the announced and implemented global tariffs as of the date of this report, and assuming such tariffs remain in place, we anticipate a significant increase in our cost of revenues for the second half of 2025, which will impact our results of operations.”
While the 2025 full-year total is not explicitly restated, the Q1 2026 report confirms that capital expenditures increased in 2025 as planned to build infrastructure. (1 met, 1 in progress across 2 tracked commitments)
“We expect these capital investments to range between $625 million and $675 million in 2025, the majority of which will be facilities-related investments.”
See the full cited Management analysis of Intuitive Surgical, Inc. - Common Stock
How durable is the business?
Revenue from instruments and accessories grew 20% year-over-year, maintaining its position as the primary revenue engine, driven by a 19% increase in da Vinci procedure volume and a 52% jump in Ion procedures. (5 expanding)
“U.S. $ 1,933.2... % of Revenue — U.S. 67%”
Service revenue grew 20% as the installed base of systems expanded to 10,763 units, providing a stable recurring income stream. (3 expanding across 1 engine)
“Instruments and accessories $ 1,734.9... 18%... Product gross profit margin 67.9%”
Systems revenue grew significantly by 33%, aided by the launch of the next-generation da Vinci 5 platform and higher average selling prices (ASPs). (4 expanding)
“Systems revenue increased by 33% to $590 million for the three months ended September 30, 2025... driven by an increase in da Vinci 5 system placements.”
International revenue grew 20%, with particular strength in India, South Korea, and Brazil, though its share of total revenue dipped slightly to 31%. (1 expanding)
“The third quarter 2025 OUS da Vinci procedure growth was approximately 24%... driven by several markets with particular strength in India, South Korea, and Brazil.”
The technological moat is widening with the rollout of the da Vinci 5, which features 10,000 times the computing power of previous models and new 'force feedback' capabilities. (4 expanding)
“We offer advanced instrumentation for the da Vinci 5, da Vinci X, and da Vinci Xi surgical systems... we have introduced a unique set of force feedback instruments that are only compatible with our da Vinci 5 surgical system.”
See the full cited Business Model analysis of Intuitive Surgical, Inc. - Common Stock
Where does growth come from?
The shift toward leasing is accelerating, with 58% of systems placed under operating leases this quarter compared to 52% last year, reflecting a strategic move to lower capital barriers for hospitals. (2 accelerating, 1 steady across 3 signals)
“Total da Vinci surgical system placements under leasing arrangements: 264 in Q2 2026 vs 199 in Q2 2025. ... % of Total da Vinci surgical system placements: 54%.”
Intuitive is shifting to a direct sales model in major European markets like Italy and Spain through a $533 million acquisition to capture more profit and control distribution.
“On March 1, 2026, Intuitive acquired the daVinci and Ion distribution businesses previously operated by abmedica, Abex, Excelencia Robótica... As a result of the acquisition, Intuitive assumed direct distribution responsibilities for Italy, Spain, Portugal, Malta, San Marino, and associated territories.”
Procedure growth remains robust but is showing slight deceleration compared to the prior year's high growth rates, primarily due to the normalization of patient backlogs and a modest decline in U.S. bariatric procedures. (4 decelerating, 1 steady across 5 signals)
“Approximately 47,900 Ion procedures were performed during the three months ended June 30, 2026, an increase of 36% compared to approximately 35,300 Ion procedures for the three months ended June 30, 2025.”
Margins are expanding due to manufacturing efficiencies and lower logistics costs, despite headwinds from new U.S. import tariffs. (2 accelerating, 3 decelerating across 5 signals)
“Product gross profit margin increased for the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily driven by IEEPA tariff refunds, lower logistics costs, and fixed overhead leverage.”
Growth in China faces significant risks due to new government price limits on robotic surgeries and increased competition from local Chinese companies. — China Pricing and Competition: Decelerating
“During the second quarter of 2026, China’s National Healthcare Security Administration (“NHSA”) issued guidelines establishing a unified national framework for robotic-assisted surgery pricing... system demand in China has been adversely affected by increasing competition from domestic robotic-assisted surgical system manufacturers.”
See the full cited Future Growth analysis of Intuitive Surgical, Inc. - Common Stock
What could break the thesis?
The risk is stable at a high level. The anti-corruption campaign contributed to fewer system placements in 2025 than anticipated, and the impact remains uncertain for future periods. (2 stable, 1 intensifying, 1 high-severity)
“In addition, system demand in China has been adversely affected by increasing competition from domestic robotic-assisted surgical system manufacturers as well as a broader central government focus on systematic governance... this campaign was initially launched by the Chinese government in July 2023 and has resulted in heightened scrutiny by medical institutions with respect to initiating tenders.”
The risk remains high and stable; while Intuitive won a trial against SIS in early 2025, that case is now on appeal, and a separate major class action ('Larkin') was granted class certification in March 2025, increasing potential liability scale. (4 stable, 1 high-severity)
“The Court also ruled that there is an antitrust aftermarket for the repair and replacement of EndoWrist instruments, and that Intuitive holds monopoly power in that aftermarket.”
The risk is intensifying as new tariffs imposed in early 2025 on imports from Mexico, Germany, and China increased cost of revenues by $22 million in Q3 2025 alone, compared to $48.8 million for the entire first half of the prior year. (4 intensifying, 1 stable, 1 high-severity)
“During the three and six months ended June 30, 2026, tariffs and other trade measures recognized in total cost of revenue were $20.8 million and $48.8 million, respectively.”
The risk is stable but remains a significant headwind; management notes that demand in China continues to be adversely impacted by domestic competition and a 'broader central government focus on systematic governance.' (1 stable, 1 intensifying)
“Third parties have offered, and may continue to offer, customers instruments and accessories that have been remanufactured and/or are unauthorized... could potentially result in reduced revenue, increased patient safety risks, and negative publicity.”
The risk is easing slightly in terms of revenue mix volatility; the proportion of da Vinci systems placed under operating leases fell to 54% in Q3 2025 from 58% in Q3 2024, though the total leased installed base continues to grow. (1 easing, 1 stable, 2 intensifying)
“% of Total da Vinci surgical system placements [under leasing] 54% [in 2026] 49% [in 2025]... as a proportion of total system placements increases, total systems revenue is reduced, which can create volatility in the systems revenue recognized in any given period.”
See the full cited Risk analysis of Intuitive Surgical, Inc. - Common Stock
Intuitive Surgical, Inc. - Common Stock analysis by filing period
Read the full thesis on Intuitive Surgical, Inc. - Common Stock
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.